Real-life cost savings and capacity improvements on implementation of the new BSG post-polypectomy surveillance guideline
The British Society of Gastroenterology (BSG) has recently updated its guideline for post-polypectomy surveillance.1 The now defunct 2010 guideline recommended that patients with low-risk adenomas (LRAs) should be offered either 5-year colonoscopy or no surveillance. In our experience, clinical practice tended to continue with colonoscopy surveillance.
Evidence has since emerged demonstrating that patients with LRAs are not at increased risk of colorectal cancer compared to patients with no adenomas detected at colonoscopy, nor to the unexamined general population.2,3 As a result, the new guideline recommends that patients with LRAs be followed up by participation in the national Bowel Cancer Screening Programme (BCSP) when eligible, rather than with colonoscopy surveillance. No follow-up is recommended for patients over 75 years old, but colonoscopy surveillance in 5–10 years can be considered for patients with LRAs that are >10 years younger than the lower screening age of the BCSP.
We carried out a modelling study to estimate the potential cost savings and capacity that could be generated by implementing the new guideline at our trust.
We conducted a retrospective endoscopy database analysis of patients for whom 5-year colonoscopy surveillance had been requested for LRAs between 2013 and 2018 at a London teaching hospital. We calculated the cost savings using the 2018/19 NHS tariff for diagnostic colonoscopy and an estimate of the histology costs, working under the assumption that one adenoma would be removed and sent for histological analysis in 30% of patients undergoing colonoscopy surveillance.4,5
The first model follows the 2010 guideline: all patients with LRAs undergo 5-year colonoscopy surveillance. The second and third models follow the 2019 guideline. In model 2, colonoscopy surveillance is offered to all patients aged <45 years at index colonoscopy, as bowel scope screening is offered in our area. In model 3, we assume that no patients are offered colonoscopy surveillance, as surveillance in younger patients is not mandated in the new guideline.
There were 1,035 patients identified; with a mean age of 58.5 years (standard deviation 12.6; range 23–97). The potential cost savings and capacity generated by implementing the 2019 guideline for patients with LRAs are displayed in Table 1. Under current practice we will carry out 1,035 surveillance colonoscopies for LRAs over the next 5 years, at a total cost of £438,498. Implementing the 2019 guideline will lead to an annual cost saving of £75,159 to £87,699, depending on the number of patients <45 years old offered colonoscopy surveillance, and generate capacity for 177 to 207 additional colonoscopies per year.
Using a real patient cohort, we have demonstrated that significant cost savings and capacity improvements will result from the implementation of the new BSG guideline. These savings will increase when the lower screening age of the BCSP is reduced to 50 years, as is anticipated. This is welcome news in the financially constrained NHS, and the generation of additional capacity, at no opportunity cost, will allow endoscopy units to focus their efforts on the patients most likely to benefit.
- © Royal College of Physicians 2020. All rights reserved.
References
- ↵
- Rutter MD
- ↵
- Click B
- ↵
- ↵
- Longcroft-Wheaton G
- ↵
- Hornung TA
Article Tools
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.